Austedo's drug class is a vmat2 inhibitor (vesicular monoamine transporter 2 inhibitor) What is tardive dyskinesia (td) and chorea associated with huntington’s disease 2.1 dosing information the dose of austedo xr and austedo is determined individually for each patient based on reduction of chorea or tardive dyskinesia and tolerability Table 1 displays the recommended dosage and important administration instructions of austedo xr and austedo when first prescribed to patients who are not being switched from tetrabenazine (a related vmat2 inhibitor). In a cohort of 27 participants, up to 77% reported enhancements in daily activities such as speech and eating after three months of treatment. Learn about uses, side effects, and more for austedo (deutetrabenazine), a drug that treats tardive dyskinesia and chorea related to huntington’s disease.
Reduce involuntary movements with austedo xr® (deutetrabenazine) tablets treatment for td See safety info and boxed warning. Resources for each step of the treatment journey with austedo xr teva is committed to supporting your patients with tardive dyskinesia (td) and their care partners.
WATCH
